BMC with Arthrex Angel System™ for Knee OA Outcomes

PURPOSE

To report the early clinical outcomes of pain, function and quality of life for patients who have undergone non operative treatment for knee osteoarthritis with bone marrow concentrate (BMC) produced by the Arthrex Angel System.

METHODS

The inclusion criteria for this analysis were patients enrolled in the Surgical Outcomes System™ registry that underwent intra-articular knee injections for osteoarthritis with BMC produced by the Arthrex Angel System. Standard patient reported outcome questionnaires for VAS, KOOS ADL function and KOOS Sport/Rec were administered at standard time points post treatment. Results were reported from pre-treatment out to 1 year post-treatment. The number of patients included is shown to the right.

Time Point	# of Compliant Patients
Pre-Treatment	342
6 weeks	272
3 months	223
6 months	192
1 year	105

TREND CONCLUSION

Based on these results, there appears to be a trend of improvement in pain symptoms, function and quality of life for patients being treated for knee osteoarthritis with BMC produced by the Arthrex Angel System. However, no claims can be made without further statistical analysis to determine if there is statistical significance. More patients and more scores are needed to evaluate long-term success.

RESULTS



VAS



KOOS ADL



KOOS Sport/Rec

Time Point	VAS Avg +/- STD
Pre-treatment	4.8 +/- 2.3
6 weeks	2.9 +/- 2.1
3 months	3.0 +/- 2.2
6 months	2.8 +/- 2.2
1 year	2.9 +/- 2.2

Time Point	KOOS Avg +/- STD
Pre-treatment	60.7 +/- 18.3
3 months	75.2 +/- 17.5
6 months	77.8 +/- 16.7
1 year	78.3 +/- 17.1

Time Point	KOOS Sports/Rec Avg +/- STD HOS Sports
Pre-treatment	33.6 +/- 28.6
3 months	48.9 +/- 26.5
6 months	49.2 +/- 27.6
1 year	50.9 +/- 28.6